# Tertiary lymphoid structures in genitourinary cancers: a comprehensive review

## TL;DR

This review explores how immune cell clusters called TLSs affect outcomes in different genitourinary cancers and their potential for improving cancer treatments.

## Contribution

This paper provides a comprehensive analysis of TLSs across multiple genitourinary cancers, highlighting their clinical significance and therapeutic potential.

## Key findings

- TLSs in bladder cancer correlate with better responses to BCG therapy and anti-PD-L1 treatment.
- Mature TLSs are linked to improved survival in clear cell renal cell carcinoma and penile squamous cell carcinomas.
- TLS suppression in non-seminomatous germ cell tumors is driven by SERPINB9-mediated chemokine downregulation.

## Abstract

Tertiary lymphoid structures (TLSs) are lymphoid cell clusters that form in non-lymphoid tissues in response to chronic inflammation and function as sites for localized, antigen-specific immune responses, potentially enhancing anti-tumor immunity. This review examines TLS presence, composition, and clinical significance across genitourinary (GU) cancers to evaluate their potential as prognostic and therapeutic targets. In prostate cancer, TLSs are infrequently found due to a typically immunologically inactive tumor microenvironment (TME), but when present, they correlate with improved outcomes and reduced recurrence, especially when structurally mature with active germinal centers (GCs). Bladder cancer, in contrast, demonstrates increased TLS activity, particularly in high-grade disease, with high TLS density associated with superior responses to Bacillus Calmette-Guérin (BCG) therapy and anti-PD-L1 treatment. In testicular seminomas, TLSs have been associated with a more favorable prognosis, whereas non-seminomatous germ cell tumors demonstrate TLS suppression driven by SERPINB9-mediated downregulation of chemokines that promote their development. In clear cell renal cell carcinoma (ccRCC), TLSs correlate with improved survival and enhanced immunotherapy responses, although elevated CXCL13 expression may paradoxically signal more aggressive disease. Unlike ccRCC, TLSs are infrequent in papillary and chromophobe RCC, reflecting a less-inflamed TME that likely contributes to reduced immunotherapy responsiveness and prognostic value. TLSs in penile squamous cell carcinomas show enhanced immune infiltration and improved overall survival (OS) independent of stage. Notably, mature TLSs are key for effective anti-tumor immunity, whereas immature TLSs may fail to generate an adequate response. Collectively, these findings highlight TLSs as prognostic biomarkers with prognostic value and therapeutic potential in GU malignancies.